{name}
{subtitle}
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~9 mi. (Mississauga, Canada, +145 more cities)
facility
Trillium Health Partners - Credit Valley Hospital ( Site 0102)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC
city
~12 mi. (North Park, Canada, +177 more cities)
facility
Local Institution
drug
cisplatin, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
city
~13 mi. (Toronto, Canada, +128 more cities)
facility
Princess Margaret Cancer Centre University Health Network
drug
bortezomib, +5 more drugs
drug type
cellular therapy, +4 more types
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~13 mi. (Toronto, Canada, +226 more cities)
facility
Princess Margaret Cancer Centre University Health Network
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
city
~13 mi. (Toronto, Canada, +133 more cities)
facility
Princess Margaret Cancer Centre University Health Network
drug
bortezomib, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~13 mi. (Toronto, Canada, +247 more cities)
facility
Local Institution, +1 more facility
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types